Literature DB >> 7508327

Ionotropic glutamate receptor types leading to adenosine-mediated inhibition of electrically evoked [3H]-noradrenaline release in rabbit brain cortex slices.

I von Kügelgen1, L Späth, K Starke.   

Abstract

1. Glutamate inhibits the electrically evoked release of noradrenaline in rabbit brain cortex slices; the inhibition is mediated by adenyl compounds, presumably adenosine. The aim of the present study was to identify the receptors involved in this indirect inhibitory effect of glutamate. Slices of the occipitoparietal cortex were preincubated with [3H]-noradrenaline and then superfused and stimulated by trains of 6 pulses, 100 Hz. 2. The ionotropic glutamate receptor agonists alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AM-PA; 10-100 microM), kainate (10-100 microM) and N-methyl-D-aspartate (NMDA; 30-300 microM) but not the metabotropic glutamate receptor agonist, 1-amino-1,3-cyclopentanedicarboxylate (ACPD; 10-100 microM) reduced the electrically evoked overflow of tritium. 3. The effects of AMPA, kainate and NMDA were attenuated or abolished by the adenosine A1-receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) as well as by adenosine A1-receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) as well as by adenosine deaminase but not by the alpha 2-adrenoceptor antagonist yohimbine, the gamma-aminobutyric acid (GABA) receptor antagonists, bicuculline and 2-hydroxysaclofen and the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME). 4. The NMDA receptor antagonist, 2-amino-5-phosphonopentanoate (AP5) blocked the inhibitory effect of NMDA but not that of AMPA and kainate. The non-NMDA-receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) blocked the effect of AMPA but not of kainate and NMDA. 5. In addition to decreasing the electrically evoked overflow of tritium, AMPA, kainate and NMDA but not ACPD caused a steep but transient rise of basal tritium efflux. This immediate releasing effect was not significantly changed by DPCPX, adenosine deaminase, yohimbine, bicuculline, 2-hydroxysaclofen and L-NAME (except that L-NAME enhanced the effect of kainate). AP5 and CNQX antagonized the immediate releasing effects in the same way that they antagonized the inhibition by AMPA, kainate and NMDA of the electrically evoked overflow of tritium.6. It is concluded that AMPA, kainate and NMDA, like glutamate, reduce the electrically evoked release of noradrenaline by releasing adenosine or an adenine nucleotide which is then degraded to adenosine. Activation of each of the three ionotropic glutamate receptors, AMPA, kainate and NMDA receptors, but not activation of metabotropic glutamate receptors can initiate this indirect inhibitory effect on the release of noradrenaline (as well as the known noradrenaline releasing effect).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508327      PMCID: PMC2175869          DOI: 10.1111/j.1476-5381.1993.tb13999.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  NMDA receptor agonists selectively block N-type calcium channels in hippocampal neurons.

Authors:  N I Chernevskaya; A G Obukhov; O A Krishtal
Journal:  Nature       Date:  1991-01-31       Impact factor: 49.962

Review 2.  Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors.

Authors:  D Schoepp; J Bockaert; F Sladeczek
Journal:  Trends Pharmacol Sci       Date:  1990-12       Impact factor: 14.819

3.  Quinoxalinediones selectively block quisqualate and kainate receptors and synaptic events in rat neocortex and hippocampus and frog spinal cord in vitro.

Authors:  E J Fletcher; D Martin; J A Aram; D Lodge; T Honoré
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

Review 4.  Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists.

Authors:  J C Watkins; P Krogsgaard-Larsen; T Honoré
Journal:  Trends Pharmacol Sci       Date:  1990-01       Impact factor: 14.819

Review 5.  Excitatory amino acid receptors in the vertebrate central nervous system.

Authors:  G L Collingridge; R A Lester
Journal:  Pharmacol Rev       Date:  1989-06       Impact factor: 25.468

6.  N-methyl-D-aspartate (NMDA) receptor-mediated stimulation of noradrenaline release, but not release of other neurotransmitters, in the rat brain cortex: receptor location, characterization and desensitization.

Authors:  K Fink; M Göthert; G Molderings; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

Review 7.  Transmitter release from brain slices elicited by single pulses: a powerful method to study presynaptic mechanisms.

Authors:  E A Singer
Journal:  Trends Pharmacol Sci       Date:  1988-08       Impact factor: 14.819

8.  Evoked release of endogenous adenosine from rat cortical slices by K+ and glutamate.

Authors:  K Hoehn; T D White
Journal:  Brain Res       Date:  1989-01-23       Impact factor: 3.252

9.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.

Authors:  D D Rees; R M Palmer; R Schulz; H F Hodson; S Moncada
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

10.  A comparison of N-methyl-D-aspartate-evoked release of adenosine and [3H]norepinephrine from rat cortical slices.

Authors:  K Hoehn; C G Craig; T D White
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

View more
  2 in total

1.  Presynaptic modulation by L-glutamate and GABA of sympathetic co-transmission in rat isolated vas deferens.

Authors:  Y W Kwan; M P Ngan; K Y Tsang; H M Lee; L A Chu
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

2.  Kainate receptors are involved in the glutamate-induced indirect, purinergic inhibition of [3H]-noradrenaline release in rabbit brain cortex.

Authors:  I von Kugelgen; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.